Search

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials

Boehringer Ingelheim Acquires AMAL Therapeutics

Promising Phase II Results in Chronic Kidney Disease

Boehringer Ingelheim announced promising Phase II data for people with chronic kidney disease

Targeting HER2 in cancer

Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.

How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US

Read more on how Boehringer Ingelheim supports injured veterans in making a fresh start through the use of service dogs, with the Warrior Canine Connection.

Topline results from Boehringer's Phase III IPF Study

Press release announcing topline results of Boehringer Ingelheim's Phase III FIBRONEER-IPF study in indiopathic pulmonary fibrosis

S&P Animal Health Partnering Oct 2023

Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

Boehringer Ingelheim Subsidiaries and Affiliate Companies

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers